PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) › Net IncomePROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) — Net IncomeAnnual figures by fiscal year, from SEC filings.2003: -$3.16M2004: -$4.34M2005: -$11.76M2006: -$8.87M2007: -$10.01M2008: -$10.27M2009: -$12.32M2010: -$18.55M2011: -$19.43M2012: -$12.57M2013: -$27.70M2014: -$10.24M2015: -$24.50M2016: -$24.43M2017: -$13.52M2018: -$8.15M2019: -$6.92M2020: -$6.68M2021: -$5.54M2022: -$3.55M2023: -$3.10M2024: -$4.73M2025: -$5.43M-$5.43M2003Net Income (USD)2025Fiscal YearNet IncomeChange YoY2025-$5.43M-14.8%2024-$4.73M-52.6%2023-$3.10M+12.7%2022-$3.55M+35.8%2021-$5.54M+17.0%2020-$6.68M+3.5%2019-$6.92M+15.1%2018-$8.15M+39.7%2017-$13.52M+44.7%2016-$24.43M+0.3%2015-$24.50M-139.2%2014-$10.24M+63.0%2013-$27.70M-120.4%2012-$12.57M+35.3%2011-$19.43M-4.8%2010-$18.55M-50.6%2009-$12.32M-20.0%2008-$10.27M-2.6%2007-$10.01M-12.8%2006-$8.87M+24.6%2005-$11.76M-170.8%2004-$4.34M-37.7%2003-$3.16M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share